HOME | SITE MAP | LEGAL


 
The downloadable documents are available in PDF format. To view those documents you will need the free Adobe Acrobat Reader.

 
 

October 26, 2006
4Discovery Labs Restructures Loan Arrangement with Quintiles 
October 12, 2006 @ 9:00 AM
4Discovery Labs Announces Topline Results of Surfaxin Phase 2 Clinical Trial for the Prevention and Treatment of BPD 
October 10, 2006
4Surfaxin® Treated Premature infants Require Fewer Re-intubations Compared with Animal Derived Surfactants 
September 28, 2006
4Discovery Labs Updates Progress on Manufacturing Remediation and Surfaxin® FDA Regulatory Matters 
July 28, 2006
4Discovery Labs Reports Second Quarter 2006 Financial Results 
July 26, 2006
4Discovery Labs Announces Second Quarter Conference Call and Webcast
June 27, 2006
4Discovery Labs Reports Progress on its Surfactant Manufacturing Remediation
June 21, 2006
4Pulmonary Surfactant Commercial Expert Rejoins Discovery Labs’ Executive Management Team
June 19, 2006
4Discovery Labs to Present at the Jefferies Life Sciences Conference
June 15, 2006
4Discovery Labs’ Surfaxin® Granted Orphan Drug Designation for the Prevention of Bronchopulmonary Dysplasia
June 7, 2006
4Discovery Labs Withdraws European Marketing Application for Surfaxin® 
May 10, 2006
4Discovery Labs Reports First Quarter 2006 Financial Results 
May 10, 2006
4Discovery Labs Announces First Quarter Conference Call and Webcast
May 5, 2006
4Discovery Labs Announces Corporate Reorganization and Personnel Reduction
April 25, 2006
4Discovery Labs Reports Surfaxin Manufaturing Issue
April 25, 2006
4Discovery Labs Provides Business and Financial Update
April 19, 2006
4Discovery Labs Secures $50 Million Committed Equity Financing Facility
April 12, 2006
4Discovery Labs Provides Update on Surfaxin Regulatory Progress
April 5, 2006
4Discovery Labs Receives Second Approvable Letter from FDA for Surfaxin for RDS 
March 31, 2006
4Discovery Labs Announces Preliminary Results of Phase 2 Clinical Trial in ARDS 
March 7, 2006
4Discovery Labs Presents at the SG Cowen Health Care Conference  
February 24, 2006
4Discovery Labs Grants 10 Neonatology Fellowship Awards  
February 24, 2006
4Discovery Labs Reports Fourth Quarter 2005 Financial Results and Business Progress  
February 15, 2006
4Discovery Labs to Present at the BIO CEO & Investor Conference  
February 6, 2006
4Discovery Labs Adds Senior Medical and Clinical Executives with Broad Pulmonology Expertise
February 1, 2006
4Discovery Labs to Present at the Brean Murray, Carret & Co. Conference  
January 26, 2006
4FDA Grants Discovery Labs’ Surfaxin® Fast Track Designation for Prevention and Treatment of Bronchopulmonary Dysplasia   
January 12, 2006
4Discovery Labs to Present at the JP Morgan Healthcare Conference  
December 28, 2005
4Discovery Labs’ Broadens Management Team - Hires Senior Manufacturing and Quality Executives 
December 28, 2005
4Discovery Labs to Acquire Laureate Pharma’s Manufacturing Operation in Totowa, N.J.  
December 20, 2005
4Discovery Labs Announces Completion of $20.0 Million in Registered Direct Offering  
December 14, 2005
4Discovery Labs to Raise $20.0 Million in Registered Direct Offering  
December 11, 2005
4Discovery Labs Forms a Strategic Alliance with Chrysalis Technologies to Develop Aerosolized SRT for Respiratory Diseases  
December 7, 2005
4Discovery Labs to Present at the First Albany Capital Conference  
November 3, 2005
4Discovery Labs' Reports Third Quarter Earnings and Business Progress  
October 28, 2005
4Discovery Labs' Surfaxin Granted Orphan Drug Designation for the Treatment of Bronchopulmonary Dysplasia  
October 21, 2005
4FDA Accepts Discovery Labs' Complete Response to Approvable Letter for Surfaxin  
October 20, 2005
4Discovery Labs' Surfaxin Licensed in Italy by Dompe Farmaceutici  
October 11, 2005
4Discovery Labs Files Universal Shelf Registration Statement  
September 20, 2005
4Discovery Labs to Present at the UBS Global Life Sciences Conference  
September 8, 2005
4Discovery Labs Completes Pilot Phase 2 Study of Investigational Drug Aerosurf, its Aerosolized Surfactant Delivered via Nasal CPAP
September1, 2005
4New Health Economic Data Shows Cost Benefit in using Surfaxin in RDS Babies
August 19, 2005
4Discovery Labs Provides Update on Status of Response to FDA Approvable Letter for Surfaxin
August 18, 2005
4Discovery Labs Announces Conference Call and Webcast
August 15, 2005
4Discovery Labs Provides Status of Previously Submitted Response to FDA Approvable Letter for Surfaxin
August 9, 2005
4Discovery Labs Selected as Founding Member of the NASDAQ Health Care Index
August 2, 2005
4Discovery Labs Reports Second Quarter 2005 Financial Results and Business Progress
July 29, 2005
4Discovery Labs Submits Response to FDA Approvable Letter for Surfaxin for RDS in Premature Infants
July 26, 2005
4Discovery Labs Announces Second Quarter Conference Call and Webcast
June 6, 2005
4Discovery Labs to Present at the 2005 Pacific Growth Life Sciences Conference
May 25, 2005
4Discovery Labs to Present at the Needham & Company Fourth Annual Biotechnology Conference
May 18, 2005
4New Data Shows Surfaxin Survival Benefit Continues Through One Year of Life
April 27, 2005
4Discovery Labs Reports First Quarter 2005 Financial Results and Business Progress
April 27, 2005
4Discovery Labs Announces First Quarter Conference Call and Webcast
April 4, 2005
4Discovery Labs’ Surfaxin (lucinactant) Phase 3 Results Published in Pediatrics, the Official Journal of the American Academy of Pediatrics
March 16, 2005
4Discovery Presentation at the SG Cowen Conference
March 15, 2005
4Discovery Labs Reports Fourth Quarter 2004 Financial Results and Business Progress
March 10, 2005
4Discovery Labs Announces Fourth Quarter Conference Call and Webcast
March 9, 2005
4Discovery Labs to Present at the SG Cowen 25th Annual Health Care Conference
February 25, 2005
4Discovery Labs Announces Completion of $29.1 Million Registered Direct Offering
February 23, 2005
4Discovery Presentation at the Bio CEO & Investor Conference
February 21, 2005
4Discovery Labs to Present at the Bio CEO & Investor Conference
February 18, 2005
4Discovery Labs to Raise Additional $2.6 Million in Registered Direct Offering
February 18, 2005
4Discovery Labs to Raise $26.5 Million in Registered Direct Offering
February 14, 2005
4Discovery Labs Update
February 14, 2005
4Discovery Labs Receives Approvable Letter from FDA for Surfaxin® for Respiratory Distress Syndrome in Premature Infants
February 2, 2005
4Discovery Labs at Brean Murray & Co., Inc. Institutional Investor Conference
February 1, 2005
4Discovery Labs Provides Update on FDA Review of Surfaxin NDA
February 1, 2005
4Discovery Labs Provides Update on FDA Pre-Approval Inspection Activities Pertaining to Surfaxin® NDA Status
January 6, 2005
4Discovery Labs Initiates Two Phase 2 Clinical Trials - Surfaxin® for Bronchopulmonary Dysplasia and Aerosolized SRT to Treat Neonatal Respiratory Failures


Enter your email address below to receive latest press releases from Discovery

4Fact Sheet

4Annual Report

4Quarterly Reports

4Conference Calendar

 

Discovery Laboratories, Inc. occasionally receives attention from the media in the form of television and news coverage and newspaper and magazine articles. This information is being provided to you on a information basis only. The information contained in these presentations was current as of the dates listed and reflected management’s views as of those dates. The presentations contain certain forward-looking information that involve inherent risks and uncertainties, known and unknown, that could cause outcomes and results to differ materially from those expressed or implied by such statements. We undertake no obligation to publicly update any information in the presentations, which speak as of their respective dates. This website may link you to other websites that are not owned or controlled by Discovery. These links are provided for your convenience only. These sites are maintained by entities over which Discovery exercises no control. Accordingly, Discovery expressly disclaims any responsibility for the content, the accuracy of the information and/or quality of products or services provided by or advertised on these third-party sites. If you choose to hyperlink to another website, you do so at your own risk. The press releases and information stored here shall not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company. To the extent that statements in the press releases and information stored here are not strictly historical, including statements as to the Company's business strategy, outlook, objectives, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's product development, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in these releases are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Among the factors which could affect the Company's actual results and could cause results to differ from those contained in the forward-looking statements contained herein are the risk that financial conditions may change, the risk that the Company will not be able to raise additional capital or enter into additional collaboration agreements, risks relating to the progress of the Company's research and development and the development of competing therapies and/or technologies by other companies. Those associated risks and others are further described in the Company's periodic filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-KSB, 8-K, 10-QSB and 10-Q, and amendments thereto.